Sleep-related eye symptoms and their potential for identifying driver sleepiness

To assess dry eye symptoms (DES) and quality of sleep in engineering students during the Covid19 pandemic lockdown and also to assess the association between DES and sleep quality. A cross-sectional questionnaire-based study was carried out among 396 engineering students studying in Saveetha engineering college. The study tool used was a semi-structured google form questionnaire designed for assessing digital device usage, symptoms of dry eye disease and sleep pattern. Responses were analyzed using appropriate statistical tests. Overall 64.1% attained a score of more than 10, indicating the presence of DES. 70.2% of the study population used digital screens for more than 13 hours. A statistically significant association was found between increased screen time and presence of DES(p<0.05). 64.9% had a score of >18 indicating reduced sleep quality. About 77.1% of the students with DES had reduced sleep quality, and a significant association (p<0.01) was observed between the two. During the Covid19 pandemic lockdown, there appears to be rising prevalence of DES in student population, one of the reasons being increased screen time. The sleep quality was also found to be reduced, and a significant association was found between DES and sleep quality.

Download Full-text

НОВЫЕ ВОЗМОЖНОСТИ КОМБИНИРОВАННОЙ ТЕРАПИИ АЛЛЕРГИЧЕСКОГО РИНИТА В УСЛОВИЯХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИ

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/raj.2019.1-1.53229 ◽

2019 ◽

Author(s):

E.V. Nazarova

Keyword(s):

Allergic Conjunctivitis ◽

Nasal Congestion ◽

Nasal Breathing ◽

Interferon Alpha 2B ◽

Complex Therapy ◽

Eye Symptoms ◽

Low Incidence ◽

The Given ◽

Combined Medication ◽

Real Clinical Practice

Статья представляет собой обзор исследовательской программы по оценке эффективности оригинального комбинированного лекарственного препарата Аллергоферон бета (бетаметазон интерферон альфа-2b) в условиях реальной клинической практики у больных сезонным аллергическим ринитом (АР). Результаты программы продемонстрировали хорошую эффективность препарата: при низкой частоте побочных эффектов наблюдалось снижение заложенности носа и восстановление носового дыхания, у пациентов с сопутствующим аллергическим конъюнктивитом отмечалось снижение выраженности глазных симптомов. Было показано, что Аллергоферон бета может быть рекомендован в качестве монотерапии у больных АР с легким и среднетяжелым течением заболевания и в комплексной терапии при тяжелом течении АР.This paper assesses the efficacy of the original combined medication Allergoferon beta (betamethasone interferon alpha-2b) in real clinical practice among patients with seasonal allergic rhinitis (AR). The research program results demonstrated a good efficacy of the given medication: there were a decrease in nasal congestion as well as restoration of nasal breathing and in patients with concomitant allergic conjunctivitis - a reduction in the severity of eye symptoms. A low incidence of side effects was observed. It was shown that Allergoferon beta can be recommended as monotherapy for patients with mild and moderate AR and in complex therapy for patients with severe AR.

Download Full-text